Repositioning Candidate Details
| Candidate ID: | R1185 |
| Source ID: | DB08910 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Pomalidomide |
| Synonyms: | Pomalidomide |
| Molecular Formula: | C13H11N3O4 |
| SMILES: | NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O |
| Structure: |
|
| DrugBank Description: | Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013. |
| CAS Number: | 19171-19-8 |
| Molecular Weight: | 273.2441 |
| DrugBank Indication: | Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. |
| DrugBank Pharmacology: | Pomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times). |
| DrugBank MoA: | Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2. |
| Targets: | Protein cereblon inhibitor; Tumor necrosis factor inhibitor; Prostaglandin G/H synthase 2 inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|